Drug profile · INN
givosiran
GIVLAARI
givosiran (GIVLAARI) is a 5-aminolevulinate synthase mrna rnai inhibitor. Associated with Lacuna Pharma Pty Ltd.
EMA: approved TGA: approved Alimentary tract and metabolism (A16) A16AX16
Patents linked 0
Pipeline programs 4
News articles 1
Drug details — givosiran
- Class
- Alimentary tract and metabolism (A16)
- Route
- —
- Patents
- 0
- Programs
- 4
- Data quality
- 0.89
Quick answer
givosiran (GIVLAARI) is a 5-aminolevulinate synthase mrna rnai inhibitor. Associated with Lacuna Pharma Pty Ltd.
Key facts
INN givosiran
Brand GIVLAARI
Mechanism 5-aminolevulinate synthase mRNA RNAi inhibitor
Target 5-aminolevulinate synthase mRNA
Therapeutic class Alimentary tract and metabolism (A16)
ATC code A16AX16
Originator Lacuna Pharma Pty Ltd
Mechanism of action
5-aminolevulinate synthase mRNA RNAi inhibitor
Primary target: 5-aminolevulinate synthase mRNA
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| TGA | approved | — |
Recent coverage
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is givosiran?
givosiran (GIVLAARI) is a 5-aminolevulinate synthase mrna rnai inhibitor. Associated with Lacuna Pharma Pty Ltd.
What is the brand name for givosiran?
GIVLAARI is a marketed brand name for givosiran. Check FDA Drugs@FDA for the current US label holder and prescribing information.